Author

J. Pierdes

Observed name: John Pierdes

Institutions: Fox Chase Cancer Center, Mercy Hospital for Women, Queen Elizabeth Hospital

Observed institutions: Fox Chase Cancer Center, St John of God Subiaco Hospital, Garvan Institute of Medical Research, Mercy Hospital for Women, Royal Hobart Hospital, UNSW Sydney, Queen Elizabeth Hospital

OpenAlex ID: A5087635497

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

2018 · Olga Kondrashova, Monique Topp, et al. · Nature Communications · 296

Prognostic gene expression signature for high-grade serous ovarian cancer

2020 · J. Millstein, T. Budden, et al. · Annals of Oncology · 155

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

2020 · Eun Young Kang, Dane Cheasley, et al. · Modern Pathology · 42

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

2024 · Ksenija Nesic, John J. Krais, et al. · Molecular Cancer · 36

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

2014 · Bo Gao, Amanda Russell, et al. · Scientific Reports · 36

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

2018 · Matthew S. Block, Robert A. Vierkant, et al. · Mayo Clinic Proceedings · 31

Timing of whole genome duplication is associated with tumor-specific MHC-II depletion in serous ovarian cancer

2024 · Nikki L. Burdett, Madelynne O. Willis, et al. · Nature Communications · 16

Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer

2023 · Nikki L. Burdett, Madelynne O. Willis, et al. · Scientific Reports · 6

Works count: 8

Citation count: 617

H-index: 7

I10-index: 7